Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bexlosteride SCHEMBL29569846 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2 | |
| Bexlosteride SCHEMBL7194610 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2 | |
| Bexlosteride SCHEMBL225679 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2 | |
| Bexlosteride SCHEMBL7798944 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2 | |
| Bexlosteride SCHEMBL225678 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2 | |
| SCHEMBL7798977 | 0.89 | SRD5A1 (0.80) | SRD5A1SRD5A2 | |
| SCHEMBL7798978 | 0.89 | SRD5A1 (0.80) | SRD5A1SRD5A2 | |
| SCHEMBL7798956 | 0.84 | SRD5A1 (1.00) | SRD5A1SRD5A2 | |
| SCHEMBL7796416 | 0.84 | SRD5A1 (1.00) | SRD5A1SRD5A2 | |
| SCHEMBL7796411 | 0.84 | SRD5A1 (1.00) | SRD5A1SRD5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3890749-B1 | CDK9 INHIBITORS AND POLYMORPHS THEREOF FOR USE AS AGENTS FOR TREATMENT OF CANCER | SUMITOMO PHARMA AMERICA INC (US) | 2025-10-29 | — | — | EP | disclosed |
| US-20250197432-A1 | CDK9 Inhibitors and Polymorphs Thereof For Use As Agents For Treatment of Cancer | SUMITOMO PHARMA ONCOLOGY INC (US) | 2025-06-19 | — | — | US | disclosed |
| US-20250100986-A1 | BISPHENOL DERIVATIVES AND THEIR USE AS ANDROGEN RECEPTOR ACTIVITY MODULATORS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2025-03-27 | — | — | US | disclosed |
| US-20250032470-A1 | Electrophilic Androgen Receptor (AR) Antagonists for AR Downregulation and Ferroptosis Induction in Cancer Cells | WAYNE STATE UNIVERSITY (US) | 2025-01-30 | — | — | US | disclosed |
| US-20240400991-A1 | IMMUNE CELLS WITH REDUCED ANDROGEN RECEPTOR (AR) LEVEL, AND METHODS OF THEIR USE TO ENHANCE ANTI-CANCER THERAPY | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2024-12-05 | — | — | US | disclosed |
| US-20240391883-A1 | HETEROCYCLIC COMPOUNDS FOR CANCER IMAGING AND TREATMENT AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2024-11-28 | — | — | US | disclosed |
| US-12133846-B2 | Electrophilic androgen receptor (AR) antagonists for AR downregulation and ferroptosis induction in cancer cells | WAYNE STATE UNIVERSITY (US) | 2024-11-05 | — | — | US | disclosed |
| EP-4446301-A2 | HETEROCYCLIC COMPOUNDS FOR CANCER IMAGING AND TREATMENT AND METHODS FOR THEIR USE | British Columbia Cancer Agency Branch (CA) | 2024-10-16 | — | — | EP | disclosed |
| US-12077554-B2 | CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer | SUMITOMO PHARMA ONCOLOGY, INC. (US) | 2024-09-03 | — | — | US | disclosed |
| EP-3988541-B1 | HETEROCYCLIC COMPOUNDS FOR CANCER IMAGING AND TREATMENT AND METHODS FOR THEIR USE | BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) | 2024-06-26 | — | — | EP | disclosed |
| US-9173939-B2 | Ester derivatives of androgen receptor modulators and methods for their use | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2015-11-03 | — | — | US | disclosed |
| US-20150010469-A1 | BISPHENOL ETHER COMPOUNDS WITH NOVEL BRIDGING GROUPS AND METHODS FOR THEIR USE | BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) | 2015-01-08 | — | — | US | disclosed |
| US-20140335080-A1 | ESTER DERIVATIVES OF ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2014-11-13 | — | — | US | disclosed |
| US-20140248263-A1 | BISPHENOL COMPOUNDS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2014-09-04 | — | — | US | disclosed |
| EP-2744773-A1 | FLUORINATED BISPHENOL ETHER COMPOUNDS AND METHODS FOR THEIR USE | British Columbia Cancer Agency Branch (CA) | 2014-06-25 | — | — | EP | disclosed |
| US-20130336962-A1 | AZIRIDINE BISPHENOL ETHERS AND RELATED COMPOUNDS AND METHODS FOR THEIR USE | The University of Biritish Columbia (CA) | 2013-12-19 | — | — | US | disclosed |
| WO-2013028572-A1 | FLUORINATED BISPHENOL ETHER COMPOUNDS AND METHODS FOR THEIR USE | BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) | 2013-02-28 | — | — | WO | disclosed |
| US-20130045204-A1 | FLUORINATED BISPHENOL ETHER COMPOUNDS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2013-02-21 | — | — | US | disclosed |
| WO-2012145328-A1 | DIBENZYLPHENYL COMPOUNDS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2012-10-26 | — | — | WO | disclosed |
| WO-2012145330-A1 | FLUORENE-9-BISPHENOL COMPOUNDS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2012-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250100986-A1 | BISPHENOL DERIVATIVES AND THEIR USE AS ANDROGEN RECEPTOR ACTIVITY MODULATORS | AR, SHBG, NR5A1 | SRD5A1 17/4885SRD5A2 29/4885 |
| US-20240391883-A1 | HETEROCYCLIC COMPOUNDS FOR CANCER IMAGING AND TREATMENT AND METHODS FOR THEIR USE | AR, KLK3, GNRHR | SRD5A1 10/4885SRD5A2 42/4885 |
| US-20130336962-A1 | AZIRIDINE BISPHENOL ETHERS AND RELATED COMPOUNDS AND METHODS FOR THEIR USE | ESR1, AR, ESR2 | SRD5A1 492/4885SRD5A2 413/4885 |
| US-20130045204-A1 | FLUORINATED BISPHENOL ETHER COMPOUNDS AND METHODS FOR THEIR USE | AR, ESRRA, ESR1 | SRD5A1 126/4885SRD5A2 175/4885 |
| US-20150010469-A1 | BISPHENOL ETHER COMPOUNDS WITH NOVEL BRIDGING GROUPS AND METHODS FOR THEIR USE | AR, ESR2, ESR1 | SRD5A1 118/4885SRD5A2 85/4885 |
| US-20140335080-A1 | ESTER DERIVATIVES OF ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | AR, ESRRA, KLK3 | SRD5A1 36/4885SRD5A2 42/4885 |
| US-12133846-B2 | Electrophilic androgen receptor (AR) antagonists for AR downregulation and ferroptosis induction in cancer cells | AR, GSR, GPX1 | SRD5A1 340/4885SRD5A2 358/4885 |
| US-20140248263-A1 | BISPHENOL COMPOUNDS AND METHODS FOR THEIR USE | AR, SHBG, ESRRA | SRD5A1 245/4885SRD5A2 149/4885 |
| US-20250032470-A1 | Electrophilic Androgen Receptor (AR) Antagonists for AR Downregulation and Ferroptosis Induction in Cancer Cells | AR, GSR, GPX1 | SRD5A1 340/4885SRD5A2 358/4885 |
| US-20250197432-A1 | CDK9 Inhibitors and Polymorphs Thereof For Use As Agents For Treatment of Cancer | CDK9, CDK19, CDK7 | SRD5A1 1765/4885SRD5A2 2395/4885 |
| US-12077554-B2 | CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer | CDK9, CDK19, CDK7 | SRD5A1 1765/4885SRD5A2 2395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.